文献速递淋巴瘤白血病

慢性淋巴细胞白血病患者发生Richter综合征转化为霍奇金淋巴瘤的生存预测因素

Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
PubMed 文献 · Am J Hematol · 2017-04-18

该研究报道了10个意大利中心管理的4680例慢性淋巴细胞白血病(CLL)患者中33例(0.7%)发生霍奇金淋巴瘤(HL)转化(Richter综合征罕见变异型)的临床与生物学特征。HL诊断时中位年龄70岁,从CLL诊断至HL的中位间隔为90个月,79%为晚期,50%国际预后评分(IPS)≥4。ABVD方案是最常用治疗(22例,66.6%),完全缓解(CR)率68%,IPS(P=0.03)和距末次CLL治疗间隔(P=0.057)影响CR;HL生存受IPS(P=0.006)和距末次CLL治疗时间(P=0.047)影响,ABVD获CR是唯一显著独立预测生存因素(P=0.037)。

要点

  • CLL发生HL转化罕见(33/4680,0.7%),诊断时多属晚期且IPS≥4者占50%。
  • ABVD方案最常用(66.6%),CR率68%,受IPS(P=0.03)和距末次CLL治疗间隔(P=0.057)影响。
  • ABVD获CR是HL转化患者生存的唯一显著独立预测因素(P=0.037)。

核心结论

  • IPS和距既往CLL治疗间隔影响ABVD方案后CR的获得,而ABVD获CR是CLL发生HL转化患者生存的最重要预测因素。

研究设计与样本

  • 在10个意大利中心管理的4680例CLL患者中,报告了33例(0.7%)发生霍奇金淋巴瘤(HL)转化患者的临床与生物学特征。

主要发现

  • HL诊断时中位年龄70岁(范围46-82),从CLL诊断至HL的中位间隔为90个月(范围0-258),3例同时诊断。
  • HL特征:晚期占79%,IPS≥4占50%,结外受累占39%,B症状占70%。
  • 82%患者曾接受CLL治疗,其中67%包含氟达拉滨;87%病例在同一活检组织中检测到CLL与HL共存。
  • ABVD方案给药22例(66.6%),ABVD后CR率为68%,受IPS(P=0.03)和距末次CLL治疗间隔(P=0.057)影响。
  • HL生存受IPS(P=0.006)和距末次CLL治疗时间(P=0.047)影响;ABVD获CR是唯一显著独立预测生存因素(P=0.037)。

关键数值与推荐

  • CLL发生HL转化比例为33/4680(0.7%);HL诊断时中位年龄70岁(范围46-82);CLL至HL中位间隔90个月(范围0-258)。
  • HL晚期占79%,IPS≥4占50%,结外受累占39%,B症状占70%;82%曾接受CLL治疗,67%含氟达拉滨。
  • ABVD后CR率68%,IPS影响CR的P=0.03,距末次CLL治疗间隔影响CR的P=0.057。
  • IPS影响HL生存的P=0.006,距末次CLL治疗时间影响HL生存的P=0.047;ABVD获CR预测生存的P=0.037。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We hereby report the clinical and biologic features of 33 of 4680 (0.7%) patients with chronic lymphocytic leukemia (CLL), managed at 10 Italian centers, who developed Hodgkin lymphoma (HL), a rare variant of Richter syndrome. The median age at CLL and at HL diagnosis were 61 years (range 41-80) and 70 years (range 46-82), respectively, with a median interval from CLL to the diagnosis of HL of 90 months (range 0-258). In 3 cases, CLL and HL were diagnosed simultaneously. Hl was characterized by advanced stage in 79% of cases, International Prognostic Score (IPS) ≥4 in 50%, extranodal involvement in 39%, B symptoms in 70%. Prior treatment for CLL had been received by 82% of patients and included fludarabine in 67%. Coexistence of CLL and HL was detected in the same bioptic tissue in 87% of cases. The most common administered treatment was the ABVD regimen given to 22 patients (66.6%). The complete response (CR) rate after ABVD was 68%, and was influenced by the IPS (P = .03) and interval from the last CLL treatment (P = .057). Survival from HL was also influenced by the IPS (P = .006) and time from the last CLL treatment (P = .047). The achievement of CR with ABVD was the only significant and independent factor predicting survival (P = .037). Taken together, our results show that the IPS and the interval from the prior CLL treatment influence the likelihood of achieving CR after ABVD, which is the most important factor predicting survival of patients with CLL developing HL.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Mauro FR, Galieni P, Tedeschi A, et al. Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma. Am J Hematol. 2017. PMID: 28295527. doi:10.1002/ajh.24714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。